Epigenetics assay developer, VolitionRx is conducting several studies intended to show that its nucleosome-based Nu.Q Cancer test can improve lung cancer screening, treatment selection, and disease monitoring.
Since its commercial launch in 2015, MGI’s DNBSEQ technology has aimed to transform next-generation sequencing by improving accuracy, enhancing cost efficiency, and providing an alternative to conventional platforms.
Applied Biosystems released the first commercial qPCR instrument nearly 30 years ago. In this GenomeWeb Executive Q&A video, Damien Luk, senior director of product management at Thermo Fisher Scientific, discusses how he believes the technology will continue to evolve.
While the therapeutic promise of ADCs is clear, success in this space depends on more than just the drug itself — it relies heavily on precise and reliable diagnostic testing.
In this GenomeWeb Executive Q&A, Foresight Diagnostics’ chief operating and compliance officer Sandra Close and chief business officer John Truesdell discuss the new guidelines, how they may change the treatment journey for diffuse large B-cell lymphoma patients, and Foresight's approach to establishing the clinical utility of its tests.
This article highlights the impact of liquid biopsies, challenges in the space, and how current technologies are helping to push the boundaries of precision medicine.
In this GenomeWeb Executive Q&A, director of procurement sustainability Alyssa Caddle and senior product manager Steve Lewis discuss Thermo Fisher’s biobased plastics and how they fit into the company's broader sustainability efforts.
The allure of faster turnaround times suggests quicker insights and potentially fewer sequencing requirements, but these disruptive solutions often overlook a critical element: the importance of high-quality, reproducible, and confident insights.
The sequencer joins the established DNBSEQ-T7 high-throughput and DNBSEQ-G99 compact throughput platforms, each capable of high-quality processing in just under 24 hours, according to the company.
The ability to measure NfL levels with high sensitivity in mouse models is transforming how researchers study neurological disorders, allowing for earlier and more precise insights into disease mechanisms and therapeutic responses.
